Literature DB >> 7582474

Contractile actions of thrombin receptor-derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems.

J Tay-Uyboco1, M C Poon, S Ahmad, M D Hollenberg.   

Abstract

1. We studied the structure-activity profiles of four thrombin receptor-derived polypeptides (TRPs) (P5, SFLLR; P5-NH2, SFLLR-NH2; P7, SFLLRNP; P7-NH2, SFLLRN) in contractile human placental artery (PA), umbilical artery (UA) and umbilical vein (UV) preparations and in a human platelet aggregation assay. 2. The contractile actions of the TRPs in the two arterial preparations were endothelium-independent, whereas in the UV tissue a contractile response was observed only in an endothelium-denuded preparation; no endothelium-mediated relaxation responses were observed in any of the vascular preparations. 3. In the three vascular preparations, the contractile responses required extracellular calcium and were attenuated by the tyrosine kinase inhibitor, genistein. 4. The relative contractile orders of potencies of the TRPs in the three vascular preparations were distinct from each other (PA: P7-NH2 > P7 > P5-NH2 > P5; UA: P7-NH2 > or = P5-NH2 approximately = P7 > > P5; UV: P5-NH2 > > P7-NH2 = P7 > > P5) and these were in turn distinct from the potency order observed in the platelet aggregation assay (P5-NH2 > or = P7-NH2 > P7 > > P5). 5. Despite the markedly dissimilar TRP potency orders in the placental artery and umbilical vein preparations, the cDNA sequences for the thrombin receptor obtained by polymerase chain reaction cloning of cDNA from the two tissue sources were identical. 6. We conclude that the four tissues studied possess functionally distinct thrombin receptor systems that interact in a distinct way with agonist peptides. In view of the identity of the thrombin receptor cDNA in the two tissues displaying the most dissimilar structure-activity profiles, we suggest that in different tissues, differences in post-translational receptor processing or differences in receptor-effector coupling interactions may result in unique thrombin receptor systems that can display distinct structure-activity profiles.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582474      PMCID: PMC1908486          DOI: 10.1111/j.1476-5381.1995.tb14970.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Responses of aortic smooth muscle to thrombin and thrombin analogues.

Authors:  D A Walz; G F Anderson; J W Fenton
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

2.  Molecular cloning of a potential proteinase activated receptor.

Authors:  S Nystedt; K Emilsson; C Wahlestedt; J Sundelin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

3.  Comparison of responses elicited by alpha-thrombin in isolated canine basilar, coronary, mesenteric, and renal arteries.

Authors:  R P White; Y Shirasawa; J T Robertson
Journal:  Blood Vessels       Date:  1984

4.  Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets.

Authors:  M G Davey; E F Lüscher
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

5.  Characterization of the thrombin-induced contraction of vascular smooth muscle.

Authors:  V M Haver; D H Namm
Journal:  Blood Vessels       Date:  1984

6.  Thrombin-elicited contractile responses of aortic smooth muscle.

Authors:  D A Walz; G F Anderson; R E Ciaglowski; M Aiken; J W Fenton
Journal:  Proc Soc Exp Biol Med       Date:  1985-12

7.  Mechanisms of adenosine triphosphate-, thrombin-, and trypsin-induced relaxation of rat thoracic aorta.

Authors:  R M Rapoport; M B Draznin; F Murad
Journal:  Circ Res       Date:  1984-10       Impact factor: 17.367

8.  Release of endothelium-derived relaxing factor from human umbilical vessels.

Authors:  J Van de Voorde; H Vanderstichele; I Leusen
Journal:  Circ Res       Date:  1987-04       Impact factor: 17.367

9.  Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery.

Authors:  J G De Mey; M Claeys; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

10.  Cerebral arterial contractions induced by human and bovine thrombin.

Authors:  R P White; C E Chapleau; M Dugdale; J T Robertson
Journal:  Stroke       Date:  1980 Jul-Aug       Impact factor: 7.914

View more
  6 in total

1.  Contractile actions of proteinase-activated receptor-derived polypeptides in guinea-pig gastric and lung parenchymal strips: evidence for distinct receptor systems.

Authors:  M Saifeddine; B Al-Ani; S Sandhu; S J Wijesuriya; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1).

Authors:  N Vergnolle; M D Hollenberg; J L Wallace
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  Enhanced contractile response to thrombin in the pregnant rat myometrium.

Authors:  Y Shintani; K Hirano; J Nishimura; H Nakano; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro.

Authors:  Michele Tognetto; Michael R D'Andrea; Marcello Trevisani; Remo Guerrini; Severo Salvadori; Lorella Spisani; Carlo Daniele; Patricia Andrade-Gordon; Pierangelo Geppetti; Selena Harrison
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport.

Authors:  N Vergnolle; W K Macnaughton; B Al-Ani; M Saifeddine; J L Wallace; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

6.  Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Authors:  Xavier Charest-Morin; Arvind Raghavan; Matthew L Charles; Tadeusz Kolodka; Johanne Bouthillier; Mélissa Jean; Mark S Robbins; François Marceau
Journal:  Pharmacol Res Perspect       Date:  2015-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.